FrancophonIA/ELRC3.0 huggingface dataset:
English: The CMDh proposed to shorten the time for recall of the products with only obstetric indications and for which revocation is applicable to ensure that prompt action is taken on products with no marketing authorisation.
Danish: CMDh foreslog at afkorte tiden til tilbagekaldelse af de produkter, der kun havde obstetriske indikationer, og for hvilke markedsføringstilladelsen skal inddrages, for at sikre øjeblikkelig indgriben over for produkter uden markedsføringstilladelse.
English: Some of the products for oral use or suppositories referred in this procedure are authorised only in obstetric indications.
Danish: Nogle af de orale produkter eller suppositorier, der er omfattet af denne procedure, er kun godkendt til obstetriske indikationer.
English: A review of safety data for fenoteral showed that the cardiovascular events tachycardia and palpitations were frequently reported in clinical studies and are listed as very common side effects of the drug.
Danish: En gennemgang af sikkerhedsdata for fenoterol viste, at de kardiovaskulære hændelser takykardi og palpitationer ofte indberettes i kliniske undersøgelser og beskrives som meget almindelige bivirkninger af lægemidlet.
English: Removal of these indications as per the PRAC recommendation will result to the revocation of these marketing authorisations.
Danish: Når disse indikationer ophæves i overensstemmelse med PRAC's anbefaling, vil det medføre inddragelse af markedsføringstilladelserne.
English: As part of the risk minimisation measures the PRAC proposed revised indications for the parenteral formulations taking all the data into account, and making clear the conditions for which these products are indicated.
Danish: Som led i risikominimeringsforanstaltningerne foreslog PRAC reviderede indikationer for de parenterale formuleringer med hensyntagen til alle data og med præcisering af de tilstande, som disse produkter er indiceret til.
English: Even after correction of potentially confounding variables, the relationship remained significant between long-term oral terbutaline therapy for preterm labour and subsequent peripartum cardiomyopathy.
Danish: Selv efter korrektion for potentielt konfunderende variable var der fortsat signifikant sammenhæng mellem langvarig oral terbutalin-behandling af for tidlige veer og efterfølgende peripartum kardiomyopati.
English: In contrast to other SABAs, no maternal fatality and no case of myocardial infarction have been reported following hexoprenaline administration for tocolysis.
Danish: Modsat andre SABA er der ikke registreret maternel dødelighed og ingen tilfælde af myokardieinfarkt efter administration af hexoprenalin med henblik på tokolyse.
English: With the exception of reports on rhabdomyolysis and SCARs, the cases were mostly in accordance with the known safety profile of ritodrine.
Danish: Bortset fra indberetningerne om rhabdomyolyse og svære kutane bivirkninger svarede de fleste af disse tilfælde til den kendte sikkerhedsprofil af ritodrin.
English: The PRAC as well recommended that the use of the parental formulations for ECV and emergency is considered favourable where these indications are already authorised.
Danish: PRAC anbefalede desuden, at anvendelse af de parenterale formuleringer til ekstern vending og akutte situationer anses for fordelagtig, hvor disse indikationer i forvejen er godkendt.
English: SABAs should not be used in women with a history of heart disease or in conditions of the mother or foetus in which prolongation of the pregnancy is hazardous.
Danish: SABA må ikke anvendes hos kvinder med hjertesygdom i anamnesen eller i tilfælde, hvor moderens eller fosterets tilstand bevirker, at forlængelse af graviditeten er farlig.
English: There is hardly any evidence of maternal death in these studies and very limited data on adverse foetal outcomes (e.g. tachycardia, hyperinsulinaemia).
Danish: Der er stort set ingen evidens om maternel død i disse undersøgelser og meget begrænsede data om uønskede udfald for fostret (f.eks. takykardi, hypoinsulinæmi).
English: a. Oral and suppository formulations which are only authorised in the indications proposed to be removed (in accordance with changes to the product information as set out in Annex III) should have their marketing authorisations revoked and should be recalled within given deadlines.
Danish: a. For de orale formuleringer og suppositorieformuleringer, der kun er godkendt til de indikationer, som foreslås ophævet (i overensstemmelse med ændringerne af produktinformationen, der fremgår af bilag III), bør markedsføringstilladelserne inddrages og produkterne tages af markedet inden for de fastlagte frister.
English: Patients should be closely monitored for signs of cardiovascular adverse reactions throughout treatment.
Danish: Patienterne bør overvåges tæt for tegn på kardiovaskulære bivirkninger i hele behandlingsperioden.
English: Having noted the above, the PRAC concluded that the benefit-risk balance is not favourable for the oral formulations and suppositories in view of the overall available safety data, in particular in relation to the risk of serious cardiovascular events, and limited efficacy.
Danish: I betragtning af ovenstående konkluderede PRAC, at benefit/risk-forholdet på baggrund af alle de foreliggende sikkerhedsdata ikke er gunstigt for de orale formuleringer og suppositorierne, navnlig vedrørende risikoen for alvorlige kardiovaskulære hændelser, og den begrænsede virkning.
English: Hexoprenaline
Danish: Hexoprenalin
English: Therefore, in accordance with Articles 31 and 32 of Directive 2001/83/EC, the PRAC recommends the variation to the terms of the marketing authorisations, or revocation, as applicable, for all medicinal products referred to in Annex I and for which the amendments to the product information are set out in Annex III of the recommendation.
Danish: anbefaler PRAC i henhold til bestemmelserne i artikel 31 og 32 i direktiv 2001/83/EF derfor ændring, eller i givet fald inddragelse, af markedsføringstilladelserne for alle lægemidler omhandlet i bilag I, for hvilke ændringerne i produktinformationen fremgår af bilag III til anbefalingen.
English: Having considered the cardiovascular adverse reactions profile associated with the use of these medicinal products in obstetric indications, the PRAC concluded that oral forms and suppositories should no longer be used to supress contractions of the womb.
Danish: Efter gennemgang af den kardiovaskulære bivirkningsprofil ved anvendelse af disse lægemidler til obstetriske indikationer konkluderede PRAC, at orale former og suppositorier ikke længere burde anvendes til hæmning af kontraktioner af livmoderen.
English: More serious adverse drug reactions have been recorded individually - chest pain, dyspnoea, ileus, loss of consciousness, arrhythmia and also several case reports of pulmonary oedema (four in a publication by Van Iddekinge et al., 1991, one in the EV database, four in the PSUR) have been reported.
Danish: Enkeltvis er der registreret mere alvorlige lægemiddelreaktioner - brystsmerter, dyspnø, ileus, bevidsthedstab, arytmi samt flere case-rapporter om lungeødem (fire i en publikation af Van Iddekinge et al., 1991, en i virksomhedens database, fire i PSUR).
English: The PRAC identified serious limitations of the efficacy data for oral and suppository formulations, and noted the available new evidence and/or current medical knowledge on the use of these products for obstetric indications.
Danish: PRAC fandt alvorlige begrænsninger i data om virkning for orale formuleringer og suppositorieformuleringer og noterede sig den foreliggende nye evidens og/eller nuværende medicinske viden om anvendelsen af disse produkter til obstetriske indikationer.
English: For the oral tablet, three serious AEs were reported (loss of consciousness, trismus and a serious skin reaction), and six nonserious AEs for the tablet.
Danish: For den orale tablet blev der indberettet tre alvorlige bivirkninger (bevidsthedstab, trismus og en alvorlig hudreaktion) og seks ikke-alvorlige bivirkninger.
English: The seriousness of AEs seems to be directly related to the dose of ritodrine administered to the patient, but also to the treatment duration as most of life-threatening AEs occurred after prolonged ritodrine administration (>72h to months).
Danish: Alvorligheden af bivirkningerne synes at have direkte sammenhæng med den administrerede dosis, men også med behandlingsvarigheden, da de fleste livstruende bivirkninger optrådte efter længerevarende administration af ritodrin (fra >72 timer til måneder).
English: The use of SABAs in emergency conditions and to enable external cephalic version is supported as this reflects limited duration of use and minimal dosing, and from a safety perspective these indications should be maintained, where authorised.
Danish: Anvendelse af SABA til akut behandling og til at muliggøre ekstern fostervending støttes, da der er tale om begrænset anvendelsesvarighed og minimal dosering, og fra et sikkerhedsperspektiv bør disse indikationer opretholdes, hvor de er godkendt.
English: Previous safety reviews have highlighted the risk of myocardial ischaemia associated with the use of SABAs in obstetric indications and that these products should be used with caution in tocolysis, and other obstetric indications.
Danish: Ved tidligere gennemgange af sikkerheden fremhævedes risikoen for myokardieiskæmi ved anvendelse af SABA til obstetriske indikationer og nødvendigheden af forsigtighed ved anvendelse af disse produkter til tokolyse og til andre obstetriske indikationer.
English: Oral formulations and suppositories are used for the maintenance in tocolysis after the injectable forms have been administered, and considering the cardiovascular safety profile, the PRAC considers that these medicinal products no longer demonstrate a favourable benefit-risk balance.
Danish: Orale formuleringer og suppositorier anvendes til vedligeholdelse af tokolyse efter administration af injektionspræparaterne, og i betragtning af den kardiovaskulære sikkerhedsprofil finder PRAC, at disse lægemidler ikke længere udviser et positivt risk/benefit-forhold.
English: Oral, parenteral and suppositories formulations have been included in this assessment.
Danish: Vurderingen omfatter orale og parenterale formuleringer samt suppositorier.
English: Maternal hypotension, palpitations, tremor, flush, sweating, headache and nausea also occurred commonly.
Danish: Maternel hypotension, palpitationer, tremor, rødmen, svedtendens, hovedpine og kvalme var også almindeligt forekommende.
English: The use of ritodrine is associated with risks of major cardiac and pulmonary dysfunction (rarely myocardial infarction), alteration in glycaemia and blood potassium concentration, gastro-intestinal disorders, tremors, headache and erythema.
Danish: Anvendelse af ritodrin er forbundet med risici for alvorlig kardial og pulmonal dysfunktion (sjældent myokardieinfarkt), ændring i glykæmi og blodets kaliumindhold, gastrointestinale lidelser, tremor, hovedpine og erytem.
English: The PRAC noted eight infant fatalities, two of which were in association with pulmonary oedema and cardiovascular events.
Danish: PRAC konstaterede desuden otte tilfælde af spædbarnsdød, heraf to knyttet til lungeødem og kardiovaskulære hændelser.
English: With regards to the window of lowest gestational viability, the PRAC noted an epidemiological review of obstetric interventions in European countries (Kollée et al, 2009) andmore recently by US (Kyser et al.,
Danish: Vedrørende vinduet med laveste levedygtighed af fosteret noterede PRAC sig en epidemiologisk oversigtsartikel om obstetriske interventioner i europæiske lande (Kollée et al, 2009) og mere nyligt fra USA (Kyser et al., 2012), som tyder på, at det er mellem 22 og 24 uger.
English: Occurrence of typical adverse effects characteristic of beta receptor stimulation are well documented, and range from mild and transient discomfort to serious cardiovascular side effects requiring prompt medical intervention, e.g. in case of arrhythmias or pulmonary oedema.
Danish: Forekomsten af typiske bivirkninger ved betareceptorstimulation er veldokumenteret og spænder fra let forbigående ubehag til alvorlige kardiovaskulære bivirkninger, der kræver øjeblikkelig lægelig indgriben ved f.eks. arytmier eller lungeødem.
English: Myocardial infarction or serious arrhythmias were not reported in the clinical trial reports available to the MAH.
Danish: Der blev ikke indberettet myokardieinfarkt eller alvorlige arytmier i de kliniske undersøgelsesrapporter, der var tilgængelige for indehaveren af markedsføringstilladelsen.
English: Fenoterol also contains descriptions of emergency uses in the indications such as dystocias in the dilation and expulsion stages of labour (such as uterine hyperactivity or spasm occurring either spontaneously or as a result of mechanical obstruction or over stimulation by oxytocic agents); intrauterine asphyxia (as indicated by signs such as foetal heart rate decelerations or incipient to moderate foetal acidosis); obstetric emergencies (such as cord prolapse or imminent uterine rupture); uterine relaxation in acute indications such as caesarean section.
Danish: For fenoterol angives desuden akutte anvendelser ved indikationer såsom dystoki i udvidelses- og uddrivningsfaserne af fødselsveer (således uterin hyperaktivitet eller spasme, enten spontan eller som følge af mekanisk obstruktion eller overstimulation med oxytocinanaloger), intrauterin asfyxi (manifesteret ved tegn såsom nedsat hjertefrekvens hos føtus eller begyndende moderat føtal acidose), akutte obstetriske indikationer (således navlestrengsfremfald eller truende uterusruptur), hæmning af uteruskontraktioner ved akutte indikationer såsom kejsersnit.
English: One case report of uterine haemorrhage exists however it is confounded by concomitant uterine pathology.
Danish: Der foreligger en case-rapport om uterin blødning, som dog er konfunderet af samtidig uterin patologi.
English: There were a number of reports of pulmonary oedema contributing to the events and one case reported pulmonary oedema in association with cardiomegaly, after taking a course of tablets for five weeks, when tocolysis failed.
Danish: I en række af indberetningerne bidrog lungeødem til hændelserne, og i et tilfælde blev der beskrevet lungeødem i tilslutning til kardiomegali efter en fem ugers tabletkur, hvor der ikke opnåedes tokolyse.
English: According to the published studies intravenous administration of hexoprenaline is very commonly accompanied with occurrence of adverse drug reactions.
Danish: Ifølge de publicerede undersøgelser er intravenøs administration af hexoprenalin meget ofte ledsaget af bivirkninger.
English: The Committee concluded that there was need for further risk minimisation measures such as information to healthcare professionals to inform on the outcome of the review and the safe use of the parenteral formulations in the obstetric indications.
Danish: • udvalget konkluderede, at der var behov for yderligere risikominimeringsforanstaltninger såsom information til sundhedspersoner om resultatet af gennemgangen og sikker anvendelse af de parenterale formuleringer til de obstetriske indikationer,
English: Isoxsuprine and hexoprenaline tablets also have ‘threatened abortion' within the indications and a posology for prophylaxis of labour.
Danish: Indikationerne for isoxsuprin og hexoprenalin tabletter omfatter desuden “truende abort”, og der angives dosering til forebyggelse af veer.
English: The Committee concluded that there was a need for further risk minimisation measures to inform healthcare professionals of the new restrictions on use and monitoring requirements introduced to ensure safe use of the parenteral formulations in the obstetric indications and to inform of the unfavourable benefit-risk balance of the oral and suppositories formulations in these indications.
Danish: Udvalget konkluderede, at der var behov for yderligere risikominimeringsforanstaltninger med henblik på at informere sundhedspersoner om de nye begrænsninger for anvendelsen og overvågningskrav, som er indført for at garantere sikker anvendelse af de parenterale formuleringer til obstetriske indikationer og for at informere om det negative benefit/risk-forhold af de orale formuleringer og suppositorieformuleringerne til disse indikationer.
English: These cases of adverse events under ritodrine therapy included both welldocumented case reports from the literature and cases recorded by the MAH from spontaneous reporting from healthcare personnel or Health Authorities.
Danish: Disse tilfælde med bivirkninger under behandling med ritodrin omfattede både veldokumenterede case-rapporter fra litteraturen og spontane indberetninger fra sundhedspersonale og sundhedsmyndigheder, som er registreret af indehaveren af markedsføringstilladelsen.
English: Post-marketing data were summarised for isoxsuprine from 2000 to 2013; no serious AEs were reported for the i.v.
Danish: Ved opgørelse af data efter markedsføring for isoxsuprin fra 2000 til 2013 fandtes ingen indberetninger om alvorlige bivirkninger for det intravenøse produkt, og tre indberetninger af ikke-alvorlige bivirkninger.
English: Salbutamol, terbutaline, fenoterol, ritodrine, hexoprenaline and isoxsuprine are authorised in obstetric indications since the 1960s.
Danish: Salbutamol, terbutalin, fenoterol, ritodrin, hexoprenalin og isoxsuprin har været godkendt til obstetriske indikationer siden 1960'erne.
English: For the oral and suppositories formulations in view of the overall available safety data, in particular in relation to the risk of serious cardiovascular events, and very limited efficacy data, the PRAC concluded in accordance with Article 116 of Directive 2001/83/EC that the benefit-risk balance is not favourable and therefore these medicinal products should no longer be indicated in the obstetrics therapeutic indication.
Danish: • for de orale formuleringer og suppositorieformuleringer tog PRAC hensyn til de foreliggende overordnede sikkerhedsdata, navnlig vedrørende risikoen for alvorlige kardiovaskulære hændelser og de meget begrænsede data om virkning, hvorfor udvalget i overensstemmelse med artikel 116 i direktiv 2001/83/EF konkluderede, at benefit/risk-forholdet ikke er positivt, og at disse lægemidler derfor ikke længere bør have denne obstetriske behandlingsindikation,
English: On 27 November 2012, further to evaluation of data resulting from pharmacovigilance activities, Hungary informed the European Medicines Agency, pursuant to Article 31 of Directive 2001/83/EC, of their consideration that the risk-benefit balance of short-acting beta-agonists (SABAs) containing medicinal products authorised in obstetric indications has become unfavourable, taking into account the cardiovascular events reported.
Danish: Den 27. november 2012 underrettede Ungarn i medfør af artikel 31 i direktiv 2001/83/EF Det Europæiske Lægemiddelagentur om, at det fandt, at benefit/risk-forholdet for lægemidler indeholdende korttidsvirkende beta-agonister (SABA) til obstetriske indikationer er blevet negativt i betragtning af de indberettede kardiovaskulære hændelser.
English: and oral salbutamol; it would appear that this adverse event is not specific to a particular formulation.
Danish: Mange af disse indberetninger optrådte både i forbindelse med intravenøst og oralt salbutamol; denne bivirkning synes således ikke at være specifik for en bestemt formulering.
English: Two cases of tocolysis maintained with suppositories only were also reported to develop pulmonary oedema.
Danish: Der blev derudover indberettet to tilfælde, hvor tokolyse blev opretholdt alene med suppositorier, og hvor der opstod lungeødem.
English: The authorised obstetric indications include partus prematurus, tocolysis (for some products use is restricted to particular weeks of gestation but for others no specific gestation period is specified), external cephalic version (ECV), and hyper-uterine contractility.
Danish: De godkendte obstetriske indikationer er: truende for tidlig fødsel, tokolyse (for nogle produkter er anvendelsen begrænset til bestemte gestationsuger, mens der fra andre ikke angives nogen bestemt del af graviditeten), ekstern vending og uterin hyperkontraktilitet.
English: b. All other marketing authorisations of SABAs (salbutamol, terbutaline, fenoterol, ritodrine, hexoprenaline and isoxsuprine) containing medicinal products indicated in tocolysis and other obstetric indications (see Annex I) should be varied (in accordance with changes to the product information as set out in Annex III).
Danish: b. Alle andre markedsføringstilladelser for lægemidler indeholdende SABA (salbutamol, terbutalin, fenoterol, ritodrin, hexoprenalin og isoxsuprin), der anvendes til tokolyse og andre obstetriske indikationer (se bilag I), bør ændres (svarende til ændringerne af produktinformationen, der fremgår af bilag III).
English: Ritodrine
Danish: Ritodrin
English: The short-acting beta-agonists (SABAs) (also known as beta-mimetics), salbutamol, terbutaline, fenoterol, ritodrine, hexoprenaline and isoxsuprine are all nationally authorised and have been on the market within the EU since the 1960s.
Danish: De korttidsvirkende beta-agonister(også kaldet beta-receptorstimulerende midler) salbutamol, terbutalin, fenoterol, ritodrin, hexoprenalin og isoxsuprin er alle nationalt godkendt og har været på markedet i EU siden 1960'erne.
English: The CMDh, having considered the PRAC recommendation dated 5 September 2013 pursuant to Article 107k(1) and (2) of Directive 2001/83/EC, reached an agreement on the variation or revocation as applicable of the marketing authorisations of terbutaline, salbutamol, hexoprenaline, ritodrine, fenoterol and isoxsuprine containing products for which the relevant sections of the summary of product characteristics and package leaflet are set out in Annex III and subject to the conditions set out in Annex IV.
Danish: Efter gennemgang af PRAC's anbefaling af 5. september 2013 CMDh i henhold til artikel 107k, stk. 1 og 2, i direktiv 2000/83/EF nåede CMDh til enighed om ændring eller i givet fald inddragelse af markedsføringstilladelserne for lægemidler indeholdende terbutalin, salbutamol, hexoprenalin, ritodrin, fenoterol og isoxsuprin, for hvilke de relevante afsnit af produktresuméet og indlægssedlen er gengivet i bilag III, under de betingelser, der fremgår af bilag IV.
English: With regards to parenteral SABAs (salbutamol, terbutaline, fenoterol, ritodrine, hexoprenaline and isoxsuprine) containing medicinal products in the obstetric indications, the PRAC concluded that the benefit-risk balance is favourable as the benefits continue to outweigh the risks.
Danish: Vedrørende parenterale lægemidler indeholdende SABA (salbutamol, terbutalin, fenoterol, ritodrin, hexoprenalin og isoxsuprin) til de obstetriske indikationer konkluderede PRAC, at benefit/risk-forholdet er gunstigt, da fordelene fortsat overstiger risiciene.
English: Based on all data available for all SABAs considered in this review (terbutaline, salbutamol, hexoprenaline, ritodrine, fenoterol, isoxsuprine), there is evidence that oral and suppository formulations are associated with serious and dose dependent adverse events.
Danish: De foreliggende data for alle SABA omfattet af denne gennemgang (terbutalin, salbutamol, hexoprenalin, ritodrin, fenoterol, isoxsuprin) er evidens for, at de orale formuleringer og suppositorieformuleringerne er forbundet med alvorlige dosisafhængige bivirkninger.
English: Scientific conclusions and grounds for revocation or variation as applicable to the terms of the marketing authorisations and detailed explanation for the differences from the PRAC recommendation
Danish: Videnskabelige konklusioner og begrundelse for tilbagekaldelse eller, i givet fald, ændring af markedsføringstilladelserne samt detaljeret redegørelse for afvigelserne fra anbefalingen fra PRAC (Det Europæiske Lægemiddelagenturs Udvalg for Risikovurdering inden for Lægemiddelvurdering)
English: This review by PRAC assessed all existing data in terms of safety of cardiovascular events when in use in these indications and the outcome of the review is summarised below.
Danish: Ved gennemgangen vurderede PRAC alle foreliggende sikkerhedsdata vedrørende kardiovaskulære hændelser ved anvendelse til disse indikationer.